Abalone Bio

Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone Bio's FAST Platform

The collaboration will leverage Abalone Bio's Functional Antibody Selection Technology platform for an undisclosed target

Some are calling them "miracle drugs" that have changed the lives of millions of people.

Abalone Bio, the only therapeutics biotech company measuring the large-scale activity datasets needed for AI-powered discovery and design of rare activating

Abalone Bio characterizes in vitro and ex vivo activities of novel antibody agonists produced by their FAST Platform

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes-evidenced by successful studies in therapeutic areas like cardiovascular and sleep apnea-may prove a greater market advantage.

Today, Abalone Bio, the only antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, announced a

By focusing on functional activity, Abalone Bio is advancing CB2-targeting antibodies with the potential to transform treatment for fibrosis, neuropathy, and beyond.

Explore how advancements in antibody drugs are paving the way for targeted treatments of autoimmune diseases. Learn how these therapies are revolutionising the field.

Abalone Bios CEO and co-founder, Richard Yu, Ph.D., explains the companys Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.